Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Birch pollen skin prick solution is a diagnostic allergen extract developed by Zhejiang Wolwo Bio-Pharmaceutical for the identification of IgE-mediated sensitization to birch pollen. It is primarily used in the diagnosis of allergic rhinitis and allergic conjunctivitis. The solution contains standardized allergenic proteins derived from birch pollen (typically *Betula verrucosa*). During a skin prick test, the solution is introduced into the epidermis, where it interacts with allergen-specific IgE antibodies bound to the surface of mast cells. In sensitized individuals, this interaction triggers mast cell degranulation and the release of inflammatory mediators like histamine, resulting in a visible wheal-and-flare reaction within 15-20 minutes. This reaction serves as a clinical indicator of Type I hypersensitivity to birch allergens.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on birch pollen skin prick solution.